super jili 88
Sportscaster Greg Gumbel dies from cancer at age 78
Your Secret Weapon This Holiday Shopping Season Could Be... ChatGPT?NEW YORK — The last of the crystal triangles that make up this year's Times Square New Year's Eve ball were installed Friday morning. It's the first time in 10 years that all 2,688 were replaced at once. Singer Pitbull attends the Times Square New Year's Eve Ball Crystal Installation on Friday at One Times Square in New York. Rapper Pitbull and inventor Joy Mangano were among those on hand to help the organizers of the celebration put the final pieces in place atop One Times Square, the skyscraper from which the 11,875-pound geodesic sphere drops to mark the new year. Singer Pitbull, left, and Joy Mangano, right, founder of CleanBoss, install a crystal Friday during the Times Square New Year's Eve Ball Crystal Installation at One Times Square in New York. A New Year's Eve ball was first dropped in Times Square in 1907. Built by a young immigrant metalworker named Jacob Starr, the 700-pound, 5-foot diameter ball was made of iron and wood and featured 100 25-watt lightbulbs. Six newer versions of the ball were featured in the century-plus since that first celebration. Times Square New Year's Eve Ball is displayed Friday at One Times Square in New York. The only years no ball drop occurred were 1942 and 1943, when the city instituted a nightly "dimout" during World War II to protect itself from attacks. Crowds instead celebrated the new year with a moment of silence followed by chimes rung from the base of One Times Square. As the new year approaches, many people begin thinking about their resolutions—typically focusing on physical health, saving money, or spending more time with family. One area that often gets overlooked is mental health. The pressure to "get fit" or "eat better" is well-known, but taking care of mental well-being is just as important as improving physical health, especially since mental health impacts every aspect of life. At first glance, mental health goals can seem intangible and subjective, but there are scientifically-proven ways to set achievable, measurable, and personalized mental wellness goals that will help anyone thrive in 2025. Vivian Chung Easton, a mental health therapist at Blueprint , a company focused on building AI-powered tools to help therapists, shares recommendations for setting mental health resolutions. One of the most important mental wellness goals for 2025 is to prioritize self-compassion and resilience. In a culture that often celebrates hustle and perfection, it's easy to push yourself too hard, setting unrealistic expectations that only add to stress and anxiety. But research shows that self-compassion and resilience are critical factors in coping with stress and maintaining long-term mental well-being. A 2021 study by Kristin Neff and Christopher Germer highlights that self-compassion—treating yourself with kindness when things don't go as planned—can reduce emotional distress and improve resilience. Instead of criticism for not meeting a goal or making a mistake, practice affirmations or positive self-talk. A simple goal, like being kinder to yourself during setbacks, can help reduce stress and boost mental wellness. A goal can look something like this: Making room for self-compassion this year can be a transformative step toward building resilience and enhancing overall mental health. Social connection is one of the most important factors in mental wellness, yet it's often overlooked in favor of individual self-improvement goals. Physical isolation can lead to loneliness, but social isolation is also strongly linked to mental health challenges like depression and anxiety, according to a study by Juliannee Holt-Lundstad. Meaningful relationships and community support can improve how satisfied you feel in your life on a day-to-day basis. This year, make it a goal to strengthen and nurture social connections, whether that means reconnecting with old friends, regularly scheduling family time, or joining social groups and clubs—like a book club, gym, or church group. For example, a social wellness goal can look like: Building mental wellness isn't just about managing thoughts and feelings; it's also about fostering a strong support network. Social connections are integral to building emotional resilience. Just as physical fitness is associated with physical health, mindfulness is often associated with mental fitness. However, practicing mindfulness is just as important as going for a run or lifting weights when it comes to mental wellness. Mindfulness-based practices—such as meditation, yoga, or breathing exercises—have been shown to reduce symptoms of anxiety and depression, improve focus, and boost emotional well-being according to research by Stefan Hofman in the Journal of Consulting and Clinical Psychology. Incorporating mindfulness into a routine doesn't have to be time-consuming or difficult. Start small by committing to 5–10 minutes of mindfulness practice a few times a week . Focus on breath, practice guided meditation, or even engage in mindful walking or eating. A simple goal might be: These exercises are called a practice for a reason: doing them consistently and often can strengthen your ability over time. These practices not only reduce stress in the moment but also help to build resilience over time, making it easier to handle future challenges. Whatever New Year's resolution you might have, a large obstacle is setting goals that are too ambitious or unrealistic. Whether it's aiming to exercise every day or cutting out all sugar, overambitious goals can lead to burnout and disappointment when progress isn't immediate. This is especially true for mental health goals, which often require patience and consistency. Using these suggestions for mental health goals, focus on how to personalize them to make them realistic and achievable for your life. Research from the American Psychological Association shows that people are more likely to succeed in their resolutions when they set realistic and incremental goals. Instead of vague, broad goals like "be happier" or "stress less," focus on small, concrete actions that can lead to big changes over time. One effective approach is to use SMART goals—goals that are Specific, Measurable, Achievable, Relevant, and Time-bound. For example: These specific, measurable actions make it easier to track progress and feel a sense of accomplishment along the way. Plus, they're more realistic and achievable, which increases your chances of success. It happens every year—gyms always seem to empty out before spring starts. One of the challenges of New Year's resolutions is that many people abandon their goals as early as January. However, mental health goals require ongoing attention and flexibility. Unlike weight loss or fitness goals, mental wellness is a journey, not an endpoint. Regularly tracking progress is essential. By setting aside time to evaluate personal progress, it's easier to adjust your goals and make necessary changes to keep things on track. Research shows that regular goal check-ins increase the likelihood of long-term success. Consider setting quarterly check-ins with yourself to assess your mental health goals: If you're not meeting your targets, adjust them to make them more realistic. Mental health progress doesn't always follow a straight line, so it's important to be flexible and forgiving with yourself. The new year is inherently a time of change, and that can be a helpful mindset in seeing new potential for growth and taking action. As you set your resolutions for 2025, don't forget to prioritize mental wellness. By focusing on achievable, realistic goals—you're setting yourself up for a healthier, more fulfilling year. Mental health is just as important as physical health, and nurturing it can help to reach other goals more effectively. Even if, in a month or two, you feel like you're falling behind—mental health goals can and should be flexible and adaptable. You can always adjust your approach if things aren't serving you, and check in with yourself regularly to stay on track. Goals are personal, and you're always in control. Here's to a year of growth, balance, and emotional well-being in 2025. This stor y was produced by Blueprint and reviewed and distributed by Stacker. Photo Credit: Alberto Menendez Cervero / Shutterstock As anyone who’s ever started a business knows, getting one off the ground is not for the faint of heart. Entrepreneurs face numerous challenges in the early years, from solidifying business plans to navigating the complexities of hiring employees and acquiring licenses and insurance. These hurdles often determine the fate of a startup, making the journey from an idea to a successful enterprise both difficult and uncertain. Each year, millions of Americans file new business applications , but only a fraction of these ventures transition to hiring employees. Among those that do, surviving the critical first few years can still be an uphill battle. However, survival rates differ significantly by location, influenced by a variety of factors such as economic conditions, state policies, and industry-specific demand. The good news is that businesses that weather the initial hurdles see a much greater likelihood of long-term success. This analysis explores the states where new businesses are most likely to survive their earliest years based on the latest data from the U.S. Bureau of Labor Statistics (BLS). The findings reveal important insights into how location and time impact the chances of business success. The chances of staying in business increase dramatically after the first few years Source: Simply Business analysis of U.S. Bureau of Labor Statistics data | Image Credit: Simply Business One of the most significant challenges for new business owners is simply staying in operation. The risk of failure is highest during the first year, but it diminishes considerably over time. For those businesses that survive the initial hurdles, the likelihood of long-term success grows each year. According to recent BLS data, only about 79% of businesses survive their first year, making it the most difficult period for startups. However, for businesses that survive their first year, roughly 85% make it to the next. By the fifth year, 91% of businesses manage to continue operations, and for those that reach the 10-year mark, an impressive 93% make it through to another year. These figures underscore the importance of persistence and adaptability, especially during the critical early years when the risk of failure is highest. They also highlight that while starting a business is undeniably challenging, those who endure the startup years enjoy far better odds moving forward. Washington & California lead the country in new business survival rates Source: Simply Business analysis of U.S. Bureau of Labor Statistics data | Image Credit: Simply Business New business success varies widely across the United States, with some states providing a more favorable environment for startups to thrive. Based on survival rates for the first three years of operation, Washington and California stand out as the nation’s leading states. Washington claims the top spot, with businesses in the state enjoying an 86.4% chance of surviving their first year, 89.3% in their second year, and an impressive 91.8% in their third year. These figures highlight Washington's robust support for young businesses, likely fueled by its thriving tech ecosystem and a generally favorable economic climate. California ranks second, with survival rates of 86.0% in the first year, 89.8% in the second, and 91.4% in the third. Despite challenges such as high costs of living and regulatory complexities, California’s strong economy, innovation hubs, and access to venture capital contribute to its high ranking. Outside of the West Coast, West Virginia —whose economy is deeply rooted in energy production, natural resources, and manufacturing—ranks third, boasting the highest third-year survival rates at 91.9%. North Carolina —a major banking center and home of the Research Triangle—follows closely with similar numbers. At the opposite end of the spectrum, Minnesota businesses face the toughest challenges in their early years, with only 72.3% surviving their first year and 80.2% their second. These regional differences highlight the importance of local economic conditions in shaping a startup's odds of success. For entrepreneurs planning their next move, this analysis offers insight into where businesses are thriving and where challenges are more pronounced. Factors like industry presence, regulatory environments, and access to resources can create opportunities—or hurdles—that significantly affect survival rates in the critical early years. Choosing the right location isn’t just about personal preference; it can mean the difference between failure and success. This analysis was conducted by Simply Business —an online insurance marketplace for small businesses—using 2024 data from the U.S. Bureau of Labor Statistics. For complete results, see the original post: States Where New Businesses Are Most Likely to Succeed . Photo Credit: Alberto Menendez Cervero / Shutterstock The data in this report comes from the U.S. Bureau of Labor Statistics’ Business Employment Dynamics . To determine the states where new businesses are most likely to succeed, researchers at Simply Business developed a business survival index. This index is based on a weighted average of the most recent survival rates for private-sector establishments during their first, second, and third years of operation, as of March 2024. The survival rates were calculated using sequential benchmarks. The first-year survival rate is the percentage of businesses still active one year after opening. The second-year rate is the percentage of those first-year survivors that remained operational for another year. Similarly, the third-year rate is the percentage of second-year survivors that continued into the following year. The data focuses exclusively on private-sector businesses with at least one employee. For complete results, see States Where New Businesses Are Most Likely to Succeed on Simply Business. Receive the latest in local entertainment news in your inbox weekly!Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update
Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Financial Highlights "In fiscal year 2024 we drove tremendous progress in our pipeline. It was a transformative year, marked by our first FDA approval and significant clinical milestones. The approval of LYMPHIRTM and the positive Phase 3 results for Mino-Lok® underscore our commitment to developing innovative therapies. Our team successfully responded to FDA comments related to the biologics license application for LYMPHIR and ultimately gained FDA approval. Productive engagement with the FDA regarding the positive results of our Phase 3 Mino-Lok® trial and Phase 2 Halo-Lido trial clarified our next steps for both programs. We anticipate continued engagement with the agency in the coming year and look forward to their guidance. Additionally, we are exploring strategic partnerships and licensing opportunities to maximize the potential of our portfolio and bring these important therapies to market efficiently," stated Leonard Mazur , Chairman and CEO of Citius Pharma. "Looking ahead, our priorities for fiscal year 2025 include launching LYMPHIRTM through our majority-owned subsidiary, Citius Oncology, driving the clinical and regulatory strategies for Mino-Lok® and Halo-Lido, fortifying our financial position, and applying a disciplined approach to resource allocation. We expect to launch LYMPHIR in the first half of 2025 and distribute CTOR shares to Citius Pharma shareholders by the end of the year, pending favorable market conditions. Our goal remains to deliver value for patients, healthcare providers, and shareholders. With a clear vision and a strong team, we are well-positioned to execute on our mission of bringing innovative therapies to market," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Liquidity As of September 30, 2024 , the Company had $3.3 million in cash and cash equivalents. As of September 30, 2024 , the Company had 7,247,243 common shares outstanding, as adjusted for the 1-for-25 reverse stock split of the Company's common stock, effected on November 25, 2024 . During the year ended September 30, 2024 , the Company received net proceeds of $13.8 million from the issuance of equity. The Company expects to raise additional capital to support operations. Research and Development (R&D) Expenses R&D expenses were $11.9 million for the full year ended September 30, 2024 , compared to $14.8 million for the full year ended September 30, 2023 . The decrease in R&D expenses primarily reflects the completion of the Halo-Lido trial and completion of activities related to the regulatory resubmission for LYMPHIR, offset by shutdown costs associated with the end of the Phase 3 trial for Mino-Lok. We expect research and development expenses to decrease in fiscal year 2025 as we continue to focus on the commercialization of LYMPHIR through our majority-owned subsidiary, Citius Oncology and because we have completed the Phase 3 trial for Mino-Lok. General and Administrative (G&A) Expenses G&A expenses were $18.2 million for the full year ended September 30, 2024 , compared to $15.3 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-launch and market research activities associated with LYMPHIR. General and administrative expenses consist primarily of compensation costs, professional fees for legal, regulatory, accounting and corporate development services, and investor relations expenses. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $11.8 million as compared to $6.6 million for the prior year. The increase of $5.2 million is largely due to the grant of options under the Citius Oncology stock plan. Stock-based compensation expense under the Citius Oncology stock plan was $7.5 million during the year ended September 30, 2024 , compared to $2.0 million for the year ended September 30, 2023 , as the plan was initiated in July 2023 . For the years ended September 30, 2024 and 2023, stock-based compensation expense also includes $47,547 and $130,382 , respectively, for the NoveCite stock option plan. In fiscal years 2023 and 2024, we granted options to our new employees and additional options to other employees, our directors, and consultants. Net loss Net loss was $39.4 million , or ($5.97) per share for the year ended September 30, 2024 , compared to a net loss of $32.5 million , or ($5.57) per share for the year ended September 30, 2023 , as adjusted for the reverse stock split. The increase in net loss reflects an increase in operating expense of $5.3 million offset by a decrease of $1.6 million in other income. Operating expense increased due to increases in stock-based compensation and general and administrative expenses, which were offset by decreased research and development expense. About Citius Pharmaceuticals, Inc. Citius Pharma is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024 , the FDA approved LYMPHIRTM, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com . Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR through our majority-owned subisity and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; risks related to research using our assets but conducted by third parties; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our ability to maintain compliance with Nasdaq's continued listing standards; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Pharma's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS PHARMACEUTICALS, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 ASSETS Current Assets: Cash and cash equivalents $ 3,251,880 $ 26,480,928 Inventory 8,268,766 — Prepaid expenses 2,700,000 7,889,506 Total Current Assets 14,220,646 34,370,434 Property and equipment, net — 1,432 Operating lease right-of-use asset, net 246,247 454,426 Other Assets: Deposits 38,062 38,062 In-process research and development 92,800,000 59,400,000 Goodwill 9,346,796 9,346,796 Total Other Assets 102,184,858 68,784,858 Total Assets $ 116,651,751 $ 103,611,150 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 4,927,211 $ 2,927,334 License payable 28,400,000 — Accrued expenses 17,027 476,300 Accrued compensation 2,229,018 2,156,983 Operating lease liability 241,547 218,380 Total Current Liabilities 35,814,803 5,778,997 Deferred tax liability 6,713,800 6,137,800 Operating lease liability – non current 21,318 262,865 Total Liabilities 42,549,921 12,179,662 Commitments and Contingencies Stockholders' Equity: Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding — — Common stock - $0.001 par value; 16,000,000 shares authorized; 7,247,243 and 6,354,371 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,247 6,354 Additional paid-in capital 271,440,421 253,056,133 Accumulated deficit (201,370,218) (162,231,379) Total Citius Pharmaceuticals, Inc. Stockholders' Equity 70,077,450 90,831,108 Non-controlling interest 4,024,380 600,380 Total Equity 74,101,830 91,431,488 Total Liabilities and Equity $ 116,651,751 $ 103,611,150 Reflects a 1-for-25 reverse stock split effective November 25, 2024. CITIUS PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 11,906,601 14,819,729 General and administrative 18,249,402 15,295,584 Stock-based compensation – general and administrative 11,839,678 6,616,705 Total Operating Expenses 41,995,681 36,732,018 Operating Loss (41,995,681) (36,732,018) Other Income: Interest income, net 758,000 1,179,417 Gain on sale of New Jersey net operating losses 2,387,842 3,585,689 Total Other Income Net 3,145,842 4,765,106 Loss before Income Taxes (38,849,839) (31,966,912) Income tax expense 576,000 576,000 Net Loss (39,425,839) (32,542,912) Net loss attributable to non-controlling interest 287,000 - Deemed dividend on warrant extension (1,047,312) (1,151,208) Net Loss Applicable to Common Stockholders $ (40,186,151) (33,694,120) Net Loss Per Share Applicable to Common Stockholders - Basic and Diluted $ (5.97) (5.57) Weighted Average Common Shares OutstandingAmericans Don’t Just Blame Killer for UnitedHealthcare CEO MurderKobe Sanders, Nevada beat Oklahoma St. for fifth place in Charleston
32 Great Black And White Comedies You Should Watch At Least Once
Eric Dickerson does not want Saquon Barkley to break rushing record
NexOptic Technology Corp. ( CVE:NXO – Get Free Report ) shares fell 20% on Friday . The stock traded as low as C$0.02 and last traded at C$0.02. 480,200 shares were traded during trading, an increase of 387% from the average session volume of 98,644 shares. The stock had previously closed at C$0.03. NexOptic Technology Trading Down 20.0 % The stock has a fifty day simple moving average of C$0.03 and a 200 day simple moving average of C$0.02. The company has a debt-to-equity ratio of 56.33, a quick ratio of 0.01 and a current ratio of 0.07. The firm has a market cap of C$3.90 million, a P/E ratio of -1.00 and a beta of 1.14. NexOptic Technology Company Profile ( Get Free Report ) NexOptic Technology Corp., a technology company, develops artificial intelligence and imaging products. It engages in developing All Light Intelligent Imaging Solutions (ALIIS), a suite of intelligent imaging solution that processes raw images and video in real time; and NexCompress technological solutions. Recommended Stories Receive News & Ratings for NexOptic Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NexOptic Technology and related companies with MarketBeat.com's FREE daily email newsletter .